Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of PF-06651600 and PF-06700841 in moderate to severe Crohn's disease
2017-003359-43Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ritlecitinib tosilate and brepocitinib in Crohn's disease (4 arms), sponsored by Pfizer. Primary endpoint: Primary endpoint(s) during the Induction Period. Started Apr 2018; status: completed.
02
Drugs
ritlecitinib tosilatebrepocitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-003359-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003359-43.